In both time periods, male and female patients were referred at similar rates. In 2008–11, adult patients were significantly more likely to be referred to A&E than in 2003–07. While A&E referral rates did increase for children, the small numbers involved meant the change was not statistically significant (Figure 1). At A&E encounters in both study periods, the proportion of patients who were new to the practice was much greater than the average for BEACH encounters. In both periods there were also high rates of new problems managed (and low rates of chronic problems), low medication and pathology ordering rates and high rates of procedures. Over 30% of the procedures performed were electrical tracings and another 20% were injections.
Digestive, circulatory and respiratory problems together accounted for 43% of all A&E referrals in 2008–11 and 50% in 2003–07. Digestive problems made up a significantly smaller proportion of referred problems in 2008–11 (16.1%) than in 2003–07 (22.8%). The most common individual problems managed with a referral to A&E are shown in Table 1. Fractures were the most commonly referred problem in both studies. No statistically significant differences over time were found, as confidence intervals were wide at this level of analysis. However, one can see trends between the study periods, in particular the extent to which digestive problems, pneumonia, urinary tract infection and acute myocardial infarction contributed to total referrals to A&E in each of the study periods.
Figure 1. Referral rates to A&E per 1000 encounters, by age group of patient
Table 1. Problems managed with an A&E referral
|Problem referred to A&E
||2003–07 % of problems referred (n=933)
||2008–11 % of problems referred (n=1117)
|Ischaemic heart disease
|Urinary tract infection
|Other digestive disease
|Acute myocardial infarction
Conflict of interest: none declared.
The authors thank the GP participants in the BEACH program and all members of the BEACH team. Funding contributors to BEACH between 2008–11: Australian Government Department of Health and Ageing; Australian Institute of Health and Welfare; National Prescribing Service; AstraZeneca Pty Ltd (Australia); Janssen-Cilag Pty Ltd; Merck, Sharp and Dohme (Australia) Pty Ltd; Pfizer Australia; Abbott Australasia; Sanofi-Aventis Australia Pty Ltd; GlaxoSmithKline Australia Pty Ltd; Bayer Australia Ltd; Wyeth Australia Pty Ltd.